Low-dose vaginal misoprostol versus vaginal dinoprostone insert for induction of labor beyond 41st week: A randomized trial by De Bonrostro Torralba, C. et al.
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/aogs.13556 
This article is protected by copyright. All rights reserved. 
DR CARLOS  DE BONROSTRO TORRALBA (Orcid ID : 0000-0002-8218-1460) 
 
 
Article type      : Original Research Article 
 
 
 
Low-dose vaginal misoprostol versus vaginal dinoprostone insert for 
induction of labor beyond 41st week: a randomized trial 
 
Carlos DE BONROSTRO TORRALBA                                        
                                                                , Jose 
Manuel CAMPILLOS MAZA 
Unit of Maternal-Fetal Medicine, Department of Obstetrics, Miguel Servet University 
Hospital, Zaragoza, Spain 
 
Corresponding author 
Carlos De Bonrostro Torralba  ORCID ID: https://orcid.org/0000-0002-8218-1460 
Unit of Maternal-Fetal Medicine, Department of Obstetrics, Hospital Universitario Miguel 
Servet, C/ Isabel La Católica 1-3, 50009 Zaragoza, Spain 
e-mail: cdebonrostro@gmail.com 
 
                          
ORCID ID: https://orcid.org/0000-0002-9358-031X  
                        
ORCID ID: https://orcid.org/0000-0002-3736-8306  
                        
ORCID ID: https://orcid.org/0000-0002-9161-4942  
                          
ORCID ID: https://orcid.org/0000-0003-0444-2423  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Jose Manuel Campillos Maza 
ORCID ID: https://orcid.org/0000-0002-0306-8858  
 
CONFLICTS OF INTERESTS  
The authors declare not having potential conflicts of interest. 
 
FUNDING  
The authors are financially independent. No specific founds were needed to develop this trial. 
 
 
ABSTRACT 
 
Introduction: The aim of this study was to compare the efficacy and safety of low-dose 
protocol of vaginal misoprostol and vaginal dinoprostone insert for induction of labor in 
women with post-term pregnancies. Material and methods: We designed a prospective, 
randomized, open-labeled, blinded for the end-point evaluators trial including women of at 
least 41 weeks of gestational age with uncomplicated singleton pregnancies and Bishop score 
lower than 6. They were randomized into dinoprostone or misoprostol groups in a 1:1 ratio. 
Baseline maternal data and perinatal outcomes were recorded for statistical analysis. 
Successful vaginal delivery within 24 hours was the primary outcome variable. A p value < 
0.05 was considered statistically significant. This study was registered in ClinicalTrials.gov 
(number NTC03744364). Results: We included 198 women for analysis (99 women in each 
group). Vaginal birth rate within 24 hours did not differ between groups (49.5% vs 42.4%; p 
= 0.412). When Bishop score was lower than four, dinoprostone insert showed a higher 
probability of vaginal delivery within 12 hours (17.8% vs 4%; p = 0.012). In dinoprostone 
group, it was more probable to require removal of the insert because of any adverse event 
(5.1% vs 14.1%; p = 0.051) and to show an abnormal fetal heart rate pattern during active 
labor (44.4% vs 58.6%; p = 0.047). Both groups were similar in neonatal outcomes including 
Apgar score, umbilical cord pH and Neonatal Intensive Care Unit admission. Conclusions: 
Low-dose vaginal misoprostol and vaginal dinoprostone insert seem to be equally effective 
and safe for induction of labor in pregnant women with a gestational age beyond 41 weeks. 
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Key message 
This trial compares dinoprostone and misoprostol for induction of labor in nulliparous 
women with posterm pregnancies. There were no differences between groups in vaginal 
delivery rate or perinatal outcomes. We conclude that both drugs can be equally safe and 
effective. 
 
INTRODUCTION 
 
Induction of labor is an obstetric procedure that is becoming more and more frequent through 
the years. Misoprostol is a synthetic prostaglandin with a variety of ways of administration 
with individual pharmacodynamic characteristics for each one of these administration options 
[1]. Dinoprostone is another pharmacological agent that can be used vaginally as a gel or as a 
slow-releasing insert. Both drugs are considered safe and effective for induction of labor in 
maternal or fetal conditions that may complicate pregnancies and make initiation of labor 
desirable [2].  
 
Misoprostol is an inexpensive and thermostable drug. However, it has a long-lasting effect 
and it is difficult to remove in case of undesirable maternal and fetal effects. On the contrary, 
dinoprostone vaginal insert is a drug whose cost is higher and requires refrigeration for 
storage. This device can be easily removed if any complication happens, and after 30 
minutes, its effect has already finished [3]. 
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There are some studies that have evaluated different ways of induction of labor although, 
unfortunately, different administrations regimes and ways of administration of prostaglandin 
agents make it difficult to compare several options for cervical ripening. Besides, inclusion 
criteria for different trials comparing both induction methods are heterogeneous, including 
different clinical situations that may have individual patterns for induction process (i.e. 
rupture of amniotic membranes) [4].  
 
Different authors have shown that misoprostol (particularly using 50 mcgr every four to six 
hours) can be as effective as vaginal dinoprostone insert, even achieving delivery within 24 
hours in a higher proportion of women. In contrast, vaginal dinoprostone insert may be 
associated with a lower rate of tachysystole and uterine hyperstimulation and, consequently, a 
lower risk of abnormal fetal heart tracings. This type of side effects linked to the use of 
misoprostol seem to be reduced when using low dose regimes [5, 6].  
 
The objective of this study was to compare the efficacy and safety of a low-dose protocol of 
vaginal misoprostol with a vaginal dinoprostone insert in women with post-term pregnancies 
scheduled for labor induction in the absence of any other risk factor. 
 
 
MATERIAL AND METHODS 
 
We designed a prospective, randomized, open-labeled, blinded for the end-point evaluators 
trial in Hospital Universitario Miguel Servet (Zaragoza), a Spanish tertiary hospital attending 
around 4000 births every year. All women with post-term pregnancies of at least 286 days of 
gestational age with otherwise uncomplicated singleton pregnancies were assessed in a 
Maternal-Fetal Unit by specialized obstetricians after a gestational care conducted by a 
general obstetrician and a mid-wife in a low-risk unit.  
 
A thorough medical and obstetrical history was recorded in first visit between 40+6 and 41+1 
weeks, as well as a complete gynecological exploration, a non-stressing fetal test and an 
ultrasound assessment to confirm fetal well-being. The attending obstetrician informed and 
discussed with the woman usual protocols of management of induction of labor for post-term 
pregnancies in our hospital and confirmed if the woman met the selection criteria to be 
included in this trial. 
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Inclusion criteria were: singleton uncomplicated nulliparous women with live fetus of at least 
286 days of gestational age with indication for induction of labor because of post-term 
pregnancy, absence of any contraindication for vaginal birth and a baseline Bishop score 
lower than six. Exclusion criteria were: multiple pregnancy, multiparity, stillbirth, 
oligohydramnios, suspected fetal distress, severe asthma, any known allergy or intolerance to 
prostaglandin agents or any contraindication for vaginal delivery. A verbal and written 
informed consent were obtained from all individual participants included in the study. 
 
All women of this trial were admitted at the hospital between 41+4 and 41+6 weeks. At that 
moment, and if all selection criteria were met, women were randomized into dinoprostone or 
misoprostol group in a 1:1 ratio using a computerized numerical sequence. These women 
were allocated to one of the groups after reassuring verbal consent before starting the 
induction process. Induction was carefully controlled by midwives and obstetricians and 
regular fetal monitoring was performed to ensure fetal well-being.  
 
A dinoprostone 10 mg insert (Propess; Ferring S.A.U.; Orense, Spain) was placed by the 
attending obstetrician in the posterior fornix of the vagina for 24 hours or until a labor had 
started. Vaginal misoprostol tablets were administered with repeated doses of 25 mcgr 
(Misofar 25 mcgr ; Laboratorios BIAL, S.A.; Zamudio, Spain) every four hours with a 
maximum of six doses in 24 hours. If uterine activity appeared with progressive cervical 
modifications, misoprostol administration was suspended for two hours and restarted if 
Bishop score did not improve. We considered active labor as a cervical dilation of at least 
three centimeters with a minimum cervical effacement of 80% and regular uterine 
contractions (at least one every 10 minutes). 
 
If an abnormal fetal heart rate tracing was detected during induction period, the drug was 
removed and then, continuous monitoring and oxytocin induction or urgent cesarean section 
was performed depending on the type of abnormalities detected.  
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If these women did not start labor after 24 hours, a second induction could be considered 
using the same prostaglandin agent or using a mechanical device. Artificial rupture of 
membranes and oxytocin induction was used if labor did not initiate after two failed induction 
attempts or if Bishop score was more than five after induction. 
 
If contractions subsequently became inadequate, oxytocin augmentation with artificial 
rupture of membranes was initiated at least half an hour after the removal of the dinoprostone 
insert or four hours after the last dose of misoprostol was administered. Epidural analgesia 
was provided under maternal request. Intrapartum assessment was offered as stated in our 
protocols based on recommendations given by Spanish Health Ministry. Continuous fetal 
heart rate monitoring was performed during active labor and it was considered abnormal 
when it was classified in categories II and III of American College of Obstetricians and 
Gynecologists. If needed, fetal scalp blood test was performed to confirm fetal wellbeing. 
 
We decided to use successful vaginal delivery within 24 hours after starting induction process 
as the primary outcome variable. Secondary outcome variables were successful cervical 
ripening within 24 hours defined as Bishop score of seven or more after 24 hours, interval 
time from induction to delivery, need for a second induction drug/device and vaginal delivery 
rate. Variables regarding fetal well-being during induction and labor periods (abnormal fetal 
cardiotocographic tracings, need for fetal scalp blood testing or meconium-stained liquor) 
were recorded. Induction assessments included maternal morbidity and adverse events related 
with prostaglandin use. 
 
All the information about induction, labor and perinatal period was collected on a paper form 
created specifically for this trial. A computerized database was designed for statistical 
analysis of these data using SPSS version 15.0 for Windows.  
 
Statistical analyses 
 
Although not many studies have been published comparing vaginal misoprostol (25 mcg 
every four hours) with dinoprostone 10 mg vaginal insert, we managed to stablish an 
estimated proportion of patients that could have a vaginal delivery within 24 hours in each 
group by reviewing previous literature regarding comparisons between both drugs with 
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different dosages and ways of administration. After that, we decided to set an estimated 
difference between groups of 20 % in the primary outcome variable, that required at least 85 
women recruited for each prostaglandin group, considering an alpha value 0.05 with 80% of 
statistical power and a 5% of losses to follow-up. Final analysis was performed from an 
intention-to-treat approach.  
 
Descriptive statistics were calculated for all the variables. Bivariate analysis was performed 
with Chi-square and Fisher´s exact tests for qualitative dichotomic variables. For quantitative 
variables, T-Student and Mann-Whitney test were used depending on the result of previous 
normality test for each variable. The relative risks (RRs) with corresponding 95% confidence 
intervals (CI) or the adjusted p-values were calculated. SPSS version 15.0 for Windows was 
used for statistical analysis. 
 
Ethical approval 
This study has the approval of the local ethics committee (Act N. 09/2014, Comité Ético de 
Investigación Clínica de Aragón, CEICA). This study was registered in ClinicalTrials.gov 
with registration number NTC03744364. 
 
RESULTS 
 
Finally, 260 women met the inclusion criteria between April 2014 and October 2017. Five of 
these patients refused to participate and 55 patients were excluded because of initiating 
spontaneous active labor before induction and randomization process. Two women, since 
having a Bishop score higher than six, initiated oxytocin augmentation without prostaglandin 
administration and they were excluded from final analysis. All remaining women were 
allocated to misoprostol or dinoprostone group using a computer-generated simple 
randomization list with a 1:1 allocation and they were included for statistical analysis (Figure 
1).  
 
Maternal body mass index was higher than 30 kg/m2 in a high proportion of women (72 
women, 37.3%) without differences between both groups. Regarding to other maternal-fetal 
data, there were no differences in baseline characteristics (Table 1). Women in the 
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misoprostol group received a median of three doses (interquartile range: three to four). Mean 
total dose of misoprostol was 81.5 mcgr (standard deviation 30.85).  
 
Regarding to the main outcome variable, ninety-one women achieved vaginal delivery within 
24 hours. Although there was a higher rate of vaginal birth within 24 hours in misoprostol 
group, these differences did not reach statistical significance (49.5% vs 42.4%; p= 0.412). No 
differences were found regarding vaginal birth within 12 hours (13.1% vs 7.1%; p=0.157). 
There was a lower probability of needing of a second induction method in misoprostol-
treated patients but without statistical significance (10.1% vs 18.2%; p=0.103). Furthermore, 
there were no differences in terms oxytocin induction, cesarean birth or operative vaginal 
delivery rates.  
 
We did not found differences in the duration of the induction process (Table 2). In women 
with very unfavorable cervical conditions (Bishop score less than four), there was a higher 
proportion of delivery within 12 hours in dinoprostone group (17.8% vs 4%; p = 0.012; RR = 
2.835; CI; 95% 1.02 – 7.89). Maternal adverse events were similar for both groups. Women 
in dinoprostone group had higher rates of retrieval due to any adverse event without statistical 
significance (5.1% vs 14.1%; p = 0.051) (Table 3).  
 
There was a higher risk of abnormal fetal heart rate patterns during active labor in 
dinoprostone group (58.6% vs 44.4%; p = 0.047; RR = 1.768; CI; 95% 1.01-3.11). During 
prostaglandin administration, the probability of having an abnormal fetal monitoring was 
similar between groups (12.1% vs 4%; p = 0.065). Both groups were similar in meconium-
stained liquor, need for fetal scalp blood test, suspected intrapartum distress, birthweight, 
Apgar score, umbilical cord pH or Neonatal Intensive Care Unit admission (Table 4). 
 
DISCUSSION 
 
Nowadays, prostaglandins (misoprostol and dinoprostone) are considered useful for induction 
of labor in pregnant women at term. Our data confirm that both drugs can be equally 
adequate for induction of post-term pregnancies. However, some differences could be found. 
For instance, women allocated to dinoprostone had a higher risk of abnormal fetal heart rate 
tracings during active labor. Despite of this fact, neonatal outcomes did not differ between 
groups. We observed a proportion of categories II and III tracings in both groups similar to 
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other studies considering the higher rate of abnormal tracings reported for women in their 
41st week [6]. 
 
Several studies have compared both drugs with conflicting results. The heterogeneity in 
dosages, pharmacological presentations and ways of administration make it difficult to 
stablish direct comparisons. To our knowledge, this is the first prospective trial comparing a 
low-dose protocol of vaginal misoprostol and a vaginal dinoprostone insert in such a 
homogeneous group of women. Because of a higher risk of adverse events reported in 
scientific literature in misoprostol-treated women with higher doses (50 mcgr or above), we 
implemented a low-dose protocol with 25 mcgr every four hours to minimize the risk of 
uterine hyperstimulation. 
 
In our trial, we observed no differences in most variables assessed. Similarly, a trial 
comparing vaginal dinoprostone insert and titrated oral misoprostol with 160 women found 
no differences between groups in vaginal delivery within 24 hours. However, a higher 
probability of successful induction was observed when Bishop score was less than four in 
misoprostol-treated women (72.9% vs 45.0%; p = 0.002) [7]. 
 
Generally, higher frequencies of uterine hyperstimulation are shown with higher dose of 
misoprostol. A randomized trial assessed the risk of adverse events with 200 mcgr of 
misoprostol and vaginal dinoprostone and showed a higher risk for those included in the 
misoprostol group (3.2 % vs 1.9%) with higher rates of intrapartum adverse fetal events and 
neonates admitted to Neonatal Intensive Care Unit in misoprostol-treated group (10.4% vs 
3.7%) [3]. 
 
A randomized trial that included 415 women showed that 50 mcgr of misoprostol every 6 
hours resulted in a shorter induction-to-delivery time and less oxytocin augmentation 
compared with 3 mg of vaginal dinoprostone but higher rates of tachysystole were found [8]. 
 
Some trials have used lower doses of misoprostol to reduce the risk of hyperstimulation or 
fetal distress. A randomized controlled trial aimed to compare misoprostol 25 mcgr every six 
hours with dinoprostone gel. This study found no differences between both methods. 
However, because of a limited sample size (50 patients for each group), it may not have 
enough statistical power to detect differences [9].  
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The low-dose protocol of misoprostol used in our study has been already used in comparison 
with dinoprostone. A large trial that included 592 women allocated to vaginal dinoprostone 
(2mg gel), vaginal misoprostol 25 mcgr every four hours or transcervical balloon catheter. 
Both prostaglandins showed similar outcomes [10]. A retrospective study compared 
induction of labor in women with oligohydramnios not being able to confirm differences 
between both drugs. In this case, doses of each prostaglandin used for induction of labor were 
not stated in the published data [11].   
 
Oral misoprostol has been widely used for induction of labor at term with good results. A 
study using oral misoprostol solution or vaginal dinoprostone including 481 women reported 
higher vaginal delivery rates within 12 hours (40.1% vs 21.4%; p 0.03), a shorter duration of 
labor (15.7% vs 21.3%) and a two-fold risk to have a partus precipitatus in the dinoprostone 
group (5.5% vs 2.7%; p = 0.04). In our study, women with dinoprostone had a higher 
probability of showing non-reassuring fetal heart tracings (11.1% vs 7.1%; p = 0.04). 
Nevertheless, they failed to find differences in vaginal delivery [12]. 
 
Due to the amount of studies published and the diversity in dosage and posology of each 
prostaglandin between trials, some authors have tried to summarize that scientific evidence. 
A systematic review found that vaginal misoprostol achieved a higher rate of vaginal delivery 
within 24 hours (22 trials; average RR = 0.77; 95% CI; 0.66-0.89). However, the authors 
remark that this increase could only be shown in those trials with a dosage of at least 50 mcgr 
in the first six hours. Uterine hyperstimulation seemed to be more frequent in misoprostol-
treated women (31 trials; average RR = 1.43; 95% CI; 0.97- 2.09) [6]. 
 
Besides, the authors show that oxytocin augmentation (36 trials; average RR = 0.68; 95% CI; 
0.60-0.76) and epidural analgesia (eight trials; RR = 0.92; 95% CI; 0.85-0.99) was less 
frequent in women with misoprostol. A higher risk of meconium-stained liquor was detected 
in the misoprostol group (18 trials; RR = 1.35; 95% CI; 1.13-1.61) [6]. 
 
Another meta-analysis published in 2014 comparing intracervical dinoprostone with vaginal 
misoprostol, found that misoprostol increased the rate of vaginal delivery within 24 hours 
(RR =1.27; 95% CI; 1.10-1.48; p = 0.002) with lower probability of oxytocin augmentation 
(RR=0.62; 95% CI; 0.54-0.72; p < 0.001) but higher risk of tachysystole (RR = 2.02; 95% CI; 
1.28-3.19; p = 0.003) without differences in Apgar score [13]. 
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All this evidence suggests that adverse events associated with misoprostol are dose-
dependent. In fact, most articles published demonstrate higher risk of uterine 
hyperstimulation with higher doses of this prostaglandin although fetal distress rates are 
similar in the vast majority of the publications [14,15,16,17]. Some studies show that 
misoprostol may be more effective than dinoprostone and oxytocin for induction of labor 
[18,19]. Misoprostol has been proved effective in different dosage regimes even with 
increasing doses [20]. 
 
One of the main strengths of this study is the type of design, a randomized trial with a 
homogeneous group of nulliparous women in their 41st week, one of the main indications for 
induction of labor. These strict selection criteria were stablished to avoid biases due to a 
heterogeneous sample. Consequently, these conditions could increase the internal validity of 
our results, but it could reduce the possibility of extrapolating our data to other clinical 
contexts.  
 
Because of the prospective design of this study, the possibility of missing data can be 
minimized. In addition, the variables were designed specifically to avoid bias and to avoid 
variability due to subjective variables. However, some variables had to be self-reported by 
the women and this information could be influenced by their perception of different 
symptoms during the induction process. 
 
Although a triple blinding approach was not possible because of the different pharmaceutical 
presentation and posology for each drug, we tried to reduce the risk of biases with a blinding 
for the end-point evaluator. The sample size was adequate to find differences in the primary 
outcome variable between groups and prospective design allowed a more accurate data 
collection. However, the number of women included may be insufficient to evaluate 
infrequent events or small differences between both treatments. 
 
Our results suggest that misoprostol and dinoprostone can be equally effective and with a low 
incidence of maternal-fetal complications. Stability at room temperature, simple 
administration and a reduced cost can make misoprostol a good option for labor induction. 
Intravaginal device of dinoprostone can be eventually removed easily in case of any adverse 
event and it has been proven safe even in women with a previous cesarean section. 
Furthermore, because of its slow-releasing insert, intravaginal dinoprostone does not require 
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a repeated administration of additional doses that may reduce discomfort for the women 
during the induction process. 
 
CONCLUSION 
 
Low-dose vaginal misoprostol and vaginal dinoprostone insert seem to be equally effective 
and safe methods for induction of labor in pregnant women with a gestational age beyond 41 
weeks. The choice between both options should be made by the clinician, considering the 
advantages and disadvantages of each drug in every clinical context. 
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Legends 
 
Figure 1.- Elegibility process and randomization. 
 
Table 1.- Baseline characteristics. 
 
Table 2.- Labor outcomes. 
 
Table 3.- Maternal adverse effects. 
 
Table 4.- Neonatal outcomes. 
 
 
 
Table 1.- Baseline characteristics. 
 
 
Variable Misoprostol (n=99) Dinoprostone (n=99) p value 
Maternal age (years)* 33.52 ( 5.04) 33.49 ( 4.9) 0.977 
Maternal height (cms) + 165 (160-168) 165 (160-170) 0.412 
Maternal weight (kg)* 78.12 ( 11.88) 77.39 ( 11.79) 0.665 
BMI (kg/m2) * 29.07 ( 4.57) 28.63 ( 4.29) 0.483 
Gestational age (days) + 292 (291-292) 292 (292-292) 0.633 
Initial Bishop Score + 3 (2-3) 3 (2-4) 0.412 
 
 
* Data shown as mean ( SD). 
+ Data shown as median (interquartile range: 25th centile – 75th centile).  
BMI, Body Mass Index (based on term gestation maternal weight). 
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Table 2.- Labor outcomes. 
 
 
Variable Misoprostol (n=99) Dinoprostone (n=99) p value 
Time to uterine activity after 
prostaglandin administration (h) + 
7 (5-12) 7 (4-12) 0.570 
Time to active labor (h) + 13 (8-20) 13 (9-23) 0.701 
Induction-delivery interval (h) + 21,6 (16.3-33.5) 21.7 (15-29.8) 0.637 
Delivery  12 h * 7 (7.1) 16 (16.2) 0.074 
Delivery  24 h * 57 (57.6) 55 (55.5) 0.774 
Vaginal delivery  12 h * 7 (7.1) 13 (13.1) 0.157 
Vaginal delivery  24 h * 49 (49.5) 42 (42.4) 0.412 
Need for second preinduction * 10 (10.1) 18 (18.2) 0.103 
Need for oxytocin induction * 24 (24.2) 27 (27.3) 0.626 
Operative vaginal delivery * 37 (37.4) 28 (28.3) 0.483 
Cesarean section * 22 (22.2) 26 (26.3) 0.507 
 
 
* Data shown as n (%). 
+ Data shown as median (interquartile range: 25th centile – 75th centile). 
 
 
 
 
 
 
Table 3.- Maternal adverse effects. 
 
 
Variable Misoprostol (n=99) Dinoprostone (n=99) p value 
Uterine hyperstimulation 7 (7.1) 10 (10.1) 0.447 
Poor maternal tolerance to 
prostaglandin * 
0 (0) 2 (2.0) 0.155 
Need to stop prostaglandin 
administration (for any side effect)  
5 (5.1) 14 (14.1) 0.051 
Need to use tocolytic drug 9 (9.1) 10 (10.1) 0.809 
 
 
Data shown as n (%). 
* Including shivering, vomiting, pyrexia or unbearable pain that leads to stop the prostaglandin administration.  
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Table 4.- Neonatal outcomes. 
 
 
Variable Misoprostol (n=99) Dinoprostone (n=99) p value 
Nonreassuring fetal heart rate 
during preinduction 
4 (4.0) 12 (12.1) 0.065 
Meconium-stained liquor during 
preinduction 
2 (2.0) 3 (3.0) 0.651 
Intrapartum abnormal FHR pattern  44 (44.4) 58 (58.6) 0.047 
Need for fetal scalp blood test 19 (19.2) 21 (21.2) 0.723 
Suspected intrapartum fetal 
distress* 
17 (17.2) 15 (15.2) 0.699 
Birthweight (g) + 3482.92 ( 366.8) 3475.31 ( 359.0) 0.830 
Apgar score < 4 at 1 min 1 (1.0) 1 (1.0) 1.000 
Apgar score < 7 at 5 min 0 (0) 1 (1.0) 0.316 
Umbilical cord pH < 7.10 11 (11.2) 9 (9.1) 0.620 
NICU admission 2 (2.0) 2 (2.0) 1.000 
 
 
Data shown as n (%). NICU: Neonatal Intensive Care Unit. 
* Suspected fetal distress that requires ending labor process.  
+ Expressed as mean ( SD). 
 
 
 
